Neostigmine
| Neostigmine | |
|---|---|
| Salts [] | |
|---|---|
| Neostigmine mesylate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 223.29 g/mol [1] |
| Solubility | 6.77e-02 g/L [1] |
| Predicted LogP | 1.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H19N2O2+ |
| IUPAC name | [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium |
| SMILES | CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C |
| InChI | InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1 |
| InChIKey | ALWKGYPQUAPLQC-UHFFFAOYSA-N |
| CAS number | 59-99-4 |
| UNII | 3982TWQ96G |
| PubChem CID | 4456 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Within 10-20 min (injection), with 4 hrs (by mouth) |
| Elimination half-life | 50–90 minutes |
| Duration of action | up–4 hours |
| Metabolism | Slow hydrolysis by acetylcholinesterase and also by plasma esterases |
| Excretion | Unchanged drug (up to 70%) and alcoholic metabolite (30%) are excreted in the urine |
| Routes of administration | Intramuscular, intravenous, subcutaneous, by mouth |
Neostigmine (also known as Eustigmine, Eustigmin, Prostigmine, Vagostigmine, Prostigmin, Juvastigmin, Neostigmin, Synstigmin, m-Trimethylammoniumphenyldimethylcarbamate or 3-Trimethylammoniumphenyl N,N-dimethylcarbamate) is a substance of the aniline class.
Chemistry
Salts []
Stereochemistry []
Neostigmine is achiral.
Druglikeness
Lipinski's rule of five
Neostigmine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- other nervous system drugs (N07)
- parasympathomimetics (N07A)
- anticholinesterases (N07AA)
- (N07AA01)
- neostigmine (N07AA01)
- sensory organs (S)
- ophthalmologicals (S01)
- antiglaucoma preparations and miotics (S01E)
- parasympathomimetics (S01EB)
- neostigmine (S01EB06)
MeSH Classification
Mechanism of action []
Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier. [1]
Interactions []
Medical side effects []
70 side effects listed on drug labels in SIDER 4.1 (neostigmine).
- Anaphylactic shock
- Arrhythmia
- Arthralgia
- Musculoskeletal discomfort
- Asthenia
- Atrioventricular block
- Bronchospasm
- Cardiovascular disorder
- Connective tissue disorder
- Diarrhoea
- Somnolence
- Dysarthria
- Slurred speech
- Osteoarthritis
- Dermatitis
- Rash
- Muscle contractions involuntary
- Flatulence
- Flushing
- Gastrointestinal disorder
- Cardiac arrest
- Hypersensitivity
- Hypotension
- Mediastinal disorder
- Miosis
- Muscle spasms
- Nervous system disorder
- Abnormal behaviour
- Convulsion
- Dizziness
- Shock
- Syncope
- Loss of consciousness
- Pollakiuria
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Respiratory arrest
- Nodal rhythm
- Respiratory depression
- Pulmonary function test decreased
- Hyperhidrosis
- Gastrointestinal pain
- Abdominal pain
- Mental disorder
- Coma
- Dyspnoea
- Headache
- Nausea
- Nystagmus
- Pruritus
- Salivary hypersecretion
- Tachycardia
- Urinary incontinence
- Vomiting
- Wheezing
- Dry mouth
- Agitation
- Skin disorder
- Chest discomfort
- Lacrimation increased
- Bradycardia
- Paralysis
- Laryngeal pain
- Insomnia
- Procedural complication
- Incision site complication
- Procedural nausea
- Procedural pain
- Post procedural complication
Indications
- Distention
- Dysphagia
- Intestinal atony
- Myasthenia gravis
- Urinary retention
Legal status []
- Australia: Neostigmine is a Schedule 4.
- United Kingdom: Neostigmine is Prescription only.
- United States: Neostigmine is Prescription only.[3]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4456, Neostigmine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4456
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Neostigmine. UNII: 3982TWQ96G. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3982TWQ96G
Bloxiverz- neostigmine methylsulfate injection. DailyMed. 3 March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 20:01:59 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 20:01:54 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 20:01:54 |
| gsrs | ok | 2026-11-20 20:01:56 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015472) | 2026-11-20 20:01:54 |
| kegg | ok | 2026-11-20 20:01:57 |
| pubchem | ok | 2026-11-20 20:01:54 |
| missing (no r/tripreports posts mention it) | 2026-11-20 20:01:54 | |
| sider | ok | 2026-11-20 20:01:55 |
| structure | ok | 2026-11-20 20:01:54 |
| wikipedia | ok | 2026-11-20 20:01:55 |